TY - JOUR
T1 - Nitric oxide inhibition of endothelial cell mitogenesis and proliferation
AU - Sarkar, Rajabrata
AU - Webb, R. Clinton
AU - Stanley, James C.
N1 - Funding Information:
Supported in part by National Institutes of Health grants Hl08677, HL-18575, and HL02816 Presented at the Fifty-sixthA nnual Meeting of the Society of University Surgeons, Denver, Colo., Feb. 9-11, 1995. Reprint requests: Rajabrata Sarkar, MD, Jobst Vascular Research Laboratories, A570 Medical Science Research Building 2, 1150 West Medical Center Dr., Ann Arbor, MI 48109-0654. Copyright 9 1995 by Mosby-YearB ook, Inci 0039-6060/95/$3.00 + 0 11/6/65086
PY - 1995/8
Y1 - 1995/8
N2 - Background Endothelial cell (EC) proliferation is essential in vascular repair after injury to the vessel wall. Impaired EC proliferation may be an important factor contributing to vessel wall disease. Nitric oxide (NO) inhibits proliferation of many cells, including smooth muscle cells (SMC). We tested the hypotheis that NO inhibits EC proliferation and DNA synthesis. Methods Cultured canine venous ECs were treated with NO donors: S-nitroso-N-acetylpenicillamine (SNAP), S-nitroso-glutathione (GSNO), or spermine NONOate (SP NO). Proliferation was determined by cell counts after 48 hours. Parallel proliferation studies were done with rat aortic SMC. ECs synchronized in S phase were treated with the NO donor diethylamine NONOate (DEA NO), and DNA synthesis was measured as the incorporation of tritiated thymidine, A NO antagonist, cPTIO, was used to reverse the effects of DEA NO. Results. Concentration-dependent (1 to 100 mmol/L) inhibition of EC proliferation (11% to 71% inhibition; p<0.05) was seen with SNAP. Similar inhibition of proliferation was noted with the NO donors GSNO and SP NO and in SMC treated with SNAP. DEA NO caused concentration-dependent (0.1 to 1 mmol/L) inhibition of EC DNA synthesis (39% to 85% inhibition; p<0.05), which was reversed by cPTIO. Conclusions. NO inhibits proliferation and mitogenesis of cultured ECs. This may occur in certain pathologic states, where production of NO in plaques and diseased vessels impedes reendothelialization, thus contributing to adverse thrombotic and vasospastic events.
AB - Background Endothelial cell (EC) proliferation is essential in vascular repair after injury to the vessel wall. Impaired EC proliferation may be an important factor contributing to vessel wall disease. Nitric oxide (NO) inhibits proliferation of many cells, including smooth muscle cells (SMC). We tested the hypotheis that NO inhibits EC proliferation and DNA synthesis. Methods Cultured canine venous ECs were treated with NO donors: S-nitroso-N-acetylpenicillamine (SNAP), S-nitroso-glutathione (GSNO), or spermine NONOate (SP NO). Proliferation was determined by cell counts after 48 hours. Parallel proliferation studies were done with rat aortic SMC. ECs synchronized in S phase were treated with the NO donor diethylamine NONOate (DEA NO), and DNA synthesis was measured as the incorporation of tritiated thymidine, A NO antagonist, cPTIO, was used to reverse the effects of DEA NO. Results. Concentration-dependent (1 to 100 mmol/L) inhibition of EC proliferation (11% to 71% inhibition; p<0.05) was seen with SNAP. Similar inhibition of proliferation was noted with the NO donors GSNO and SP NO and in SMC treated with SNAP. DEA NO caused concentration-dependent (0.1 to 1 mmol/L) inhibition of EC DNA synthesis (39% to 85% inhibition; p<0.05), which was reversed by cPTIO. Conclusions. NO inhibits proliferation and mitogenesis of cultured ECs. This may occur in certain pathologic states, where production of NO in plaques and diseased vessels impedes reendothelialization, thus contributing to adverse thrombotic and vasospastic events.
UR - http://www.scopus.com/inward/record.url?scp=0029156792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029156792&partnerID=8YFLogxK
U2 - 10.1016/S0039-6060(05)80334-4
DO - 10.1016/S0039-6060(05)80334-4
M3 - Article
C2 - 7638744
AN - SCOPUS:0029156792
SN - 0039-6060
VL - 118
SP - 274
EP - 279
JO - Surgery
JF - Surgery
IS - 2
ER -